What is Stalicla?
Stalicla SA is a Swiss clinical-stage biopharmaceutical firm dedicated to revolutionizing the treatment of neurodevelopmental disorders (NDDs). The company has developed a clinically validated neuro precision development platform designed to identify stratified patient subgroups, thereby enabling the advancement of personalized therapeutic strategies. This platform is central to Stalicla's approach, aiming to deliver more effective treatments by targeting specific patient populations. The company's efforts are focused on creating novel solutions for conditions that have historically presented significant challenges in treatment efficacy.
How much funding has Stalicla raised?
Stalicla has raised a total of $29.9M across 3 funding rounds:
Series A
$10M
Series B
$17.4M
Other Financing Round
$2.5M
Series A (2018): $10M, investors not publicly disclosed
Series B (2024): $17.4M, investors not publicly disclosed
Other Financing Round (2025): $2.5M supported by Addex Therapeutics
Key Investors in Stalicla
Addex Therapeutics
Addex Therapeutics is a clinical-stage pharmaceutical company specializing in the development of novel orally available small molecule drugs, particularly allosteric modulators for neurological disorders. Based in Switzerland, the company focuses on advancing treatments for conditions affecting the central nervous system.
What's next for Stalicla?
With substantial enterprise-level backing and a recent strategic investment, Stalicla is well-positioned for its next phase of growth. The company is preparing to advance its pipeline, with Phase 2 trials for its lead NDD asset, STP1, and a second asset targeting specific autism subpopulations. Furthermore, STP7 (Mavoglurant) is progressing towards Phase 3 trials, supported by US government funding. This strategic financing will be instrumental in navigating these critical clinical development stages, aiming to bring much-needed personalized therapies to patients suffering from neurodevelopmental disorders.
See full Stalicla company page
